The Hungarian Innovation Foundation has awarded Hungarian drugmaker Gedeon Richter the 2017 Innovation Grand Prize for the development of its antipsychotic drug Cariprazine, Richter said in a statement.
Cariprazine is used in the treatment of schizophrenia and bipolar disorders. It is primarily manufactured in Hungary and was developed by Hungarian researchers and developers. It is marketed in over 70% of the global pharmaceutical market, the company added.
Erik Bogsch, CEO of Gedeon Richter with the award. Photo: Bruzák Noémi/ MTI.
Gedeon Richter Plc., headquartered in Budapest, is a major drug-maker company in Central Eastern Europe, with an expanding direct presence in Western Europe. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas.